Human interleukin-2 biosimilar (Amoytop Biotech/BioGeneric Pharma)

人白细胞介素-2生物类似药 (Amoytop Biotech/BioGeneric Pharma)

Report date: 2022/01/14 13:23:58

Base Information

Drug NameHuman interleukin-2 biosimilar (Amoytop Biotech/BioGeneric Pharma)
Drug Alias Name人白细胞介素-2生物仿制药 (Amoytop Biotech/BioGeneric Pharma)rHuIL-2
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokinesBiologics > Biosimilar
Mechanisms of ActionImmunostimulantsInterleukin-2 receptor agonists
TargetsInterleukin-2 receptor
Therapy Area/IndicationsCarcinoma, Renal CellMelanoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusClinical
Highest Status in ChinaClinical
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsCarcinoma, Renal CellMelanoma
Inactive IndicationsN/A

Other Information

ATC CodeL03AC01
Related LinksN/A